Alar Pharmaceuticals Inc.

6785

TW0006785009

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
270 ^TWD	-3.57%		+12.27%	+28.88%

May. 10	Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021

August 13, 2021 at 03:31 pm EDT

Alar Pharmaceuticals Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced operating loss was TWD 35.495 million compared to TWD 103.770 million a year ago. Net loss was TWD 7.198 million compared to TWD 85.213 million a year ago. Basic loss per share was TWD 0.13 compared to TWD 1.99 a year ago.

Latest news about Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan	Mar. 07	CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023	Mar. 06	CI
Gilva Therapeutics, INC. announced that it expects to receive TWD 30 million in funding from Alar Pharmaceuticals Inc.	Mar. 04	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office	Feb. 22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office	Feb. 22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial	Feb. 19	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals	23-10-11	CI
Alar Pharmaceuticals Inc.(TPEX:6785) added to S&P Global BMI Index	23-09-18	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000	22-01-12	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-13	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients	21-03-09	CI

Chart Alar Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ALAR PHARMACEUTICALS INC.	+28.88%	559M
MERCK KGAA	+14.82%	78.65B
KYOWA KIRIN CO. LTD.	+9.32%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.16B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.31%	4.85B
YUHAN CORPORATION	+11.19%	4.19B
BETTA PHARMACEUTICALS CO., LTD.	-22.37%	2.32B
INDIVIOR PLC	+10.72%	2.29B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-30.09%	2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+20.63%	2.19B

Specialty & Advanced Pharmaceuticals